EODData

MEMBERSHIP REGISTER LOG IN

FRA, JNY: JW (Cayman) Therapeutics Co. Ltd

03 Sep 2025
LAST:

0.5800

CHANGE:
 0.06		OPEN:
0.5750		HIGH:
0.5850		ASK:
0.0000		VOLUME:
8.5K
CHG(%):
11.54		PREV:
0.5200		LOW:
0.5750		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
03 Sep 250.57500.58500.57500.58008.5K
02 Sep 250.51500.52000.51500.52008.5K
01 Sep 250.52500.52500.52500.52508.5K
28 Aug 250.50500.50500.50500.50508.5K
27 Aug 250.59000.59500.58500.58508.5K
26 Aug 250.62000.63000.62000.63008.5K
25 Aug 250.62000.63500.62000.63508.5K
22 Aug 250.61000.61000.60000.60008.5K
21 Aug 250.61000.61500.61000.61008.5K
20 Aug 250.58500.59000.58500.59008.5K

COMPANY PROFILE

Name:JW (Cayman) Therapeutics Co. Ltd
About:JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People's Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) immunotherapy for use in the treatment of a range of hematological cancers, as well as systemic lupus erythematosus (SLE), a chronic autoimmune disease. The company's products pipeline includes JWCAR129, a chimeric antigen receptor (CAR) construct therapy for use in the treatment of multiple myeloma; and JWCAR201, a dual targeting autologous CAR T-cell therapy for use in the treatment of B-cell malignancies and autoimmune diseases. It is also developing JWATM204 and JWATM214 for treating hepatocellular carcinoma (HCC); JWATM203 for the treatment of hepatoblastoma (HB) and hepatocellular carcinoma (HCC) in pediatric patients; JWATM213 for treating HCC; JWTCR001 for the treatment of various solid tumors; and JWCAR031 for the treatment of small cell lung cancer. In addition, the company engages in the drug research and development; medical research and experimental development; import and export handling; and clinical trial and CRO, as well as investment holding activities. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.
Sector:Healthcare
Industry:Biotechnology
Address:Building B, Shanghai, China
Website:https://www.jwtherapeutics.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:0.54
MA10:0.58
MA20:0.56
MA50:0.45
MA100:0.32
MA200:0.25
STO9:57.69
STO14:57.69
RSI14:56.47
WPR14:-42.31
MTM14:0.03
ROC14:0.05
ATR:0.03
Week High:0.60
Week Low:0.51
Month High:0.64
Month Low:0.50
Year High:0.64
Year Low:0.13